
2005
Selected Abstracts from the EASL
Conference – April 13-17, 2005 Paris, France
Click here
for important information on how to read an abstract
Hepatitis C
HCV Treatment
Acute Hepatitis C
- Interferon based therapies
-
Current Therapies-
- Decompensated Cirrhosis
- Interferon based therapies
- Pegasys
- PATIENTS INFECTED WITH
HCV-5 PRESENT THE SAME RESPONSE RATE THAN PATIENTS INFECTED WITH HCV-1:
RESULTS FROM THE BELGIAN RANDOMISED TRIAL FOR NAIVE AND RELAPSERS
(BERNAR) (April 16, 2005)
- COMBINED PEGYLATED
INTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT OF CHRONIC HEPATITIS C IN
EGYPT (ANRS 1211 TRIAL) (April 16, 2005)
- AGE AND SUSTAINED
VIROLOGICAL RESPONSE IN PATIENTS WITH PERSISTENTLY ‘NORMAL’ ALT AND
CHRONIC HEPATITIS C TREATED WITH PEGINTERFERON ALFA-2A (40KD) PLUS
RIBAVIRIN (April 16, 2005)
- COST-EFFECTIVENESS OF
PEGINTERFERON ALFA-2A (40KD) PLUS RIBAVIRIN IN TREATMENT OF CHRONIC
HEPATITIS C (CHC) IN HIV-HCV CO-INFECTION (April
16, 2005)
- PEGINTERFERON ALFA-2A
(40KD) PLUS RIBAVIRIN IN CIRRHOTIC PATIENTS WITH CHRONIC HEPATITIS C:
RESULTS OF A MULTICENTRE OPEN-LABEL PROGRAMME IN CANADA (April
16, 2005)
- ARE CHANGES IN
LYMPHOCYTES DURING PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN TREATMENT
IN PATIENTS WITH CO-INFECTION RELATED TO HCV RESPONSE? FINDINGS FROM
APRICOT (April 16, 2005)
- PRELIMINARY HEALTH
OUTCOMES RESULTS OF TREATMENT WITH PEGINTERFERON ALFA-2A (40KD) PLUS
RIBAVIRIN FOR CHRONIC HEPATITIS C GENOTYPE 1 IN DAILY ROUTINE CLINICAL
PRACTICE: THE HERACLES PROJECT (April 16,
2005)
- PEGINTERFERON ALFA-2A
(40KD) PLUS RIBAVIRIN IS AS EFFECTIVE IN PATIENTS RELAPSING AFTER
CONVENTIONAL INTERFERON BASED THERAPY THAN IN NAÏVE PATIENTS: RESULTS
FROM THE BERNAR-1 TRIAL (April 16, 2005)
- THE INFLUENCE OF
CUMULATIVE PEGINTERFERON ALFA-2A (40 KD) AND RIBAVIRIN (RBV) EXPOSURE ON
SUSTAINED VIROLOGICAL RESPONSE (SVR) RATES IN PATIENTS WITH GENOTYPE 1
CHRONIC HEPATITIS C (April 16, 2005)
- PEGINTERFERON ALFA-2A
(40KD) (PEG-IFN-2A) PLUS RIBAVIRIN IN
CIRRHOTIC PATIENTS WITH CHRONIC HEPATITIS C: RESULTS OF A MULTICENTRE OPEN-LABEL
EXPANDED ACCESS PROGRAM IN CANADA (April 16,
2005)
- EVIDENCE THAT SERUM
RIBAVIRIN STEADY-STATE CONCENTRATIONS DO NOT CORRELATE WITH EARLY
VIROLOGICAL RESPONSE DURING PEGINTERFERON ALFA-2A + RIBAVIRIN
COMBINATION THERAPY FOR CHRONIC HEPATITIS C (April
16, 2005)
- CLUSTERING OF POOR
PROGNOSTIC FACTORS IN PATIENTS WITH CHRONIC HEPATITIS C (April
16, 2005)
- PREDICTION OF
SUSTAINED VIROLOGICAL RESPONSE AT WEEK 4 OF PEGINTERFERON ALFA-2A (40KD)
PLUS RIBAVIRIN TREATMENT IN CHRONIC HEPATITIS C PATIENTS WITH
PERSISTENTLY ‘NORMAL’ ALT LEVELS (April 16,
2005)
- PEGINTERFERON ALFA-2A
(40KD) PLUS RIBAVIRIN IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HEPATITIS
C AND GENOTYPE 2 OR 3 INFECTION: INDIVIDUAL ESTIMATED PROBABILITY OF
SUSTAINED VIROLOGICAL RESPONSE (SVR) (April 16,
2005)
- ARE THERE DIFFERENCES
IN BASELINE CHARACTERISTICS OR TREATMENT OUTCOMES WITH PEGINTERFERON
ALFA-2A (40KD) (PEG-IFNΑ-2A) AND RIBAVIRIN IN PATIENTS INFECTED
WITH HCV GENOTYPE 1A VERSUS 1B? (April 16,
2005)
- Peg-Intron
- PEGINTERFERON
ALFA 2-B THERAPY IN ACUTE HEPATITIS C: IMPACT OF ONSET AND DURATION OF
THERAPY ON SUSTAINED VIROLOGIC RESPONSE (April 16,
2005)
- FINAL
RESULTS OF ANRS HC02 - RIBAVIC: A RANDOMIZED CONTROLLED TRIAL OF
PEGYLATED-INTERFERON ALFA-2B PLUS RIBAVIRIN VS INTERFERON ALFA-2B PLUS
RIBAVIRIN FOR NAIVE HCV-HIV CO-INFECTED PATIENTS (April 16,
2005)
- ENHANCED
ANTIVIRAL EFFICACY FOR VALOPICITABINE (NM283) PLUS PEG-INTERFERON IN
HEPATITIS C PATIENTS WITH HCV GENOTYPE-1 INFECTION: RESULTS OF A PHASE IIA MULTICENTER
TRIAL (April
16, 2005)
- EFFECT OF
MAINTENANCE PEG-INTRON THERAPY ON PORTAL HYPERTENSION AND ITS
COMPLICATIONS: RESULTS FROM THE COPILOT STUDY (April 16,
2005)
- SUSTAINED VIROLOGIC
RESPONSE (SVR) IN THE EPIC3 TRIAL: WEEK TWELVE VIROLOGY PREDICTS SVR IN
PREVIOUS INTERFERON/RIBAVIRIN TREATMENT FAILURES RECEIVING
PEG-INTRON/REBETOL (PR) WEIGHT BASED DOSING (WBD) (April
16, 2005)
- EFFICACY AND
SAFETY OF ANTIVIRAL THERAPY IN LIVER TRANSPLANT RECIPIENTS WITH CHRONIC
HEPATITIS C (April
16, 2005)
- RECURRENCE
OF HEPATITIS C VIRUS IS MORE SEVERE IN LIVER TRANSPLANTED HIV-HCV
CO-INFECTED PATIENTS THAN IN HCV MONO-INFECTED PATIENTS (April 16,
2005)
- PEGYLATED
INTERFERON AND RIBAVIRIN THERAPY DOES NOT INCREASE ACUTE REJECTION RISK
POST LIVER TRANSPLANTATION – A RETROSPECTIVE CASE CONTROL STUDY (April 16,
2005)
- PEGYLATED
INTERFERON (PEG-IFN) ALFA 2B + RIBAVIRIN (RB) IN THE TREATMENT OF
POST-LIVER TRANSPLANT (LT) RECURRENT HEPATITIS C (April 16,
2005)
- PEGYLATED-INTERFERON
ALPHA-2B PLUS RIBAVIRIN IN THE TREATMENT OF HCV REINFECTION AFTER LIVER
TRANSPLANTATION EXPERIENCE OF A SINGLE CENTRE (April 16,
2005)
- PEGYLATED
INTERFERON ALPHA PLUS TAURINE TREATMENT IN EXPERIMENTAL LIVER FIBROSIS (April 16,
2005)
- ANALYSIS OF
CCR5 RECEPTOR EXPRESSION ON CD8 T CELLS DURING CHRONIC HEPATITIS C VIRUS
(HCV) INFECTION ROLE OF PEGYLATED-INTERFERON A2B PLUS RIBAVIRIN (April 16,
2005)
- INTRAHEPATIC
HEPATITIS C VIRUS-SPECIFIC CD4+ AND CD8+ T CELL RESPONSES IN PATIENTS
WITH CHRONIC HEPATITIS C VIRUS TREATED WITH PEGINTERFERON ALPHA-2B:
RELATION TO LIVER HISTOLOGY (April
16, 2005)
- GENOME-WIDE
ANALYSIS OF THE TRANSCRIPTIONAL IFN-α RESPONSE IN PATIENTS TREATED
FOR HEPATITIS C - IDENTIFICATION OF GENES THAT ARE ASSOCIATED WITH A
STRONG ANTIVIRAL ACTIVITY (April
16, 2005)
- SAFETY AND
EFFICACY OF COMBINATION THERAPY WITH 12KD PEGYLATED INTERFERON AND
RIBAVIRIN FOR CHRONIC HEPATITIS C VIRUS INFECTION IN DECOMPENSATED
CIRRHOTICS (April
16, 2005)
- EFFICACY OF
PEG-INTERFERON ALPHA-2B (PEG-IFN) PLUS RIBAVIRIN IN RESPONDER-RELAPSERS
TO A PREVIOUS COURSE OF INTERFERON ALPHA PLUS RIBAVIRIN (April 16,
2005)
- EFFICACY OF
INTERFERON (STANDARD OR PEGYLATED) PLUS RIBAVIRIN IN NAÏVE PATIENTS WITH
HEPATITIS C VIRUS GENOTYPE 5. A FRENCH NATIONAL STUDY (April 16,
2005)
- IMPACT OF
OBESITY ON DEGREE OF LIVER DISEASE AND RESPONSE TO THERAPY IN PATIENTS
WITH CHRONIC HEPATITIS C VIRUS INFECTION (April 16,
2005)
- COST
EFFECTIVE PREDICTION OF SUSTAINED RESPONSE TO IFN ALPHA-2B OR PEG-IFN
ALPHA-2B PLUS RIBAVIRIN COMPUTING INFECTED CELLS DYNAMICS BY EARLY ALT
AND HCV-RNA DECLINE (April
16, 2005)
- HIGH EARLY
VIROLOGIC RESPONSE IN PATIENTS WITH CHRONIC HEPATITIS C, GENOTYPE 1
TREATED WITH PEGINTERFERON AND RIBAVIRIN; THE IMPACT OF GROWTH FACTORS (April 16,
2005)
- DEVELOPMENT
AND VALIDATION OF A SIMPLE MODEL TO PREDICT RESPONSE TO PEGINTERFERON
PLUS RIBAVIRIN COMBINATION THERAPY IN GENOTYPE 1 CHRONIC HEPATITIS C (April 16,
2005)
- PEGINTERFERON
ALFA-2A VERSUS PEGINTERFERON ALFA-2B IN THE TREATMENT OF CHRONIC
HEPATITIS C (April
16, 2005)
- PEGYLATED
INTERFERON ALFA-2B PLUS RIBAVIRIN IN THE RE-TREATMENT OF PATIENTS NON
RESPONSIVE TO IFN/RIBAVIRIN (April
16, 2005)
- RELEVANCE
OF RIBAVIRIN PLASMA CONCENTRATION FOR THE PREDICTION OF TREATMENT
RESPONSE (April
16, 2005)
- INFLUENCE
OF APOLIPOPROTEIN E4 ALLELE (APO E4)ON VIRAL DYNAMICS AND EARLY RESPONSE
RATE IN HCV TYPE 1-INFECTED PATIENTS TREATED WITH PEG-IFNA AND RIBAVIRIN (April 16,
2005)
- EFFICACY OF
6 MONTHS TREATMENT WITH PEG-INTERFERON ALFA-2B PLUS RIBAVIRIN (P/R) IN
PATIENTS INFECTED WITH HEPATITIS C WITH GENOTYPE 1 OF LOW VIRAL LOAD
(G1LVL) (April 16, 2005)
- HEPATIC
CYCLOOXYGENASE (COX)-2 AND RESPONSE TO COMBINED INTERFERON &
RIBAVIRIN THERAPY IN CHRONIC HEPATITIS C (April 16,
2005)
- HEPATOCYTES ACTIVATE
HSC VIA MMP-9. ROLE OF
IFN-ALPHA2B IN MODULATING LIVER FIBROSIS IN HCV PATIENTS (April
16, 2005)
- ENHANCED ANTIVIRAL
ACTIVITY OF NM107, ALONE OR IN COMBINATION WITH INTERFERON ALFA (April 16,
2005)
- INTERFERON-α
INDUCED ALTERNATIVE SPLICING IN THE THROMBOPOIETIN (TPO) -5'UTR
INTERFERES WITH TPO-RESPONSE TO THROMBOCYTOPENIA (April
16, 2005)
- QRT-PCR
ANALYSIS OF TELOMERASE MRNA EXPRESSION IN LIVER BIOPSY SPECIMENS IN
PATIENTS WITH HEPATITIS B AND C UNDERGOING ANTIVIRAL THERAPY (April 16,
2005)
- Conventional interferon
- Infergen
Diagnostic Tools –
Disease Progression–
- Estrogen
- Steatosis
- Treatment Responders
Epidemiology
Experimental Therapies–
- Interferon based therapies
- Merimepodib (VX-497)
- NM 283
- Vaccines
Viramidine
Genotype–
- Genotype 1
- Genotype 2
- Genotype 3
- Genotype 4
- Genotype 5
Occult HBV–
Predicting Treatment Response–
Quality of Life–
Retreatment–
Special Populations–
- Extrahepatic Manifestations
- Patients with Normal ALT’s
- Pediatric
- Pegasys and Special Populations
- Treatment for Non-responders / Relapsers to
Previous Therapies
Transmission–
Transplantation–
- Interferon based therapies
- Perinatal
- Special Populations – Children
Viral Kinetics–
- Interferon based therapies
Weight-Based Dosing–
- Interferon based therapies
HIV/HCV Coinfection
Current Therapies-
- Interferon based therapies
Experimental Therapies–
- Interferon based therapies
Occult HBV–
Steatosis–
Transplantation–